tbuckley/cabot-search huggingface dataset:
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group
Authors: Eirini Katodritou, Evangelos Terpos, Sossana Delimpasi, Maria Kotsopoulou, Eurydiki Michalis, Chrysanthi Vadikolia, Marie-Christine Kyrtsonis, Argiris Symeonidis, Nikolaos Giannakoulas, Chrissa Vadikolia, Michalis Michael, Christina Kalpadakis, Theodora Gougopoulou, Chrystalla Prokopiou, Georgia Kaiafa, Dimitrios Christoulas, Maria Gavriatopoulou, Evlampia Giannopoulou, Vasiliki Labropoulou, Evgenia Verrou, Efstathios Kastritis, Pavlina Konstantinidou, Achilles Anagnostopoulos, Meletios A. Dimopoulos
Journal: Blood Cancer Journal (2018)

Abstract We have studied the efficacy and the prognostic impact of novel agents in 50 primary plasma cell leukemia (pPCL) patients registered in our database. Eighty percent of patients were treated upfront with novel agent-based combinations; 40% underwent autologous stem cell transplantation (ASCT). Objective response rate was 76; 38% achieved at least very good partial response (≥vgPR) and this correlated significantly with bortezomib-based therapy plus ASCT. At the time of evaluation, 40 patients had died. Early mortality rate (≤1 month) was 6%. Median progression-free survival (PFS) and overall survival (OS) were 12 months and 18 months respectively, both significantly longer in patients treated with bortezomib-based therapy + ASCT vs. others (PFS: 18 vs. 9 months; p = 0.004, OS: 48 vs. 14 months; p = 0.007). Bortezomib-based therapy + ASCT predicted for OS in univariate analysis. In multivariate analysis, achievement of ≥vgPR and LDH ≥ 300 U/L were significant predictors for OS. These real-world data, based on one of the largest reported national multicenter series of pPCL patients treated mostly with novel agents support that, among the currently approved induction therapies, bortezomib-based regimens are highly effective and reduce the rate of early mortality whereas in combination with ASCT consolidation they prolong OS.
Cabozantinib (C) exposure-response (ER) modeling of efficacy and safety endpoints as a function of clearance in patients (pts) with renal cell carcinoma (RCC).
Authors: Eric Jonasch, Robert J. Motzer, Bernard Escudier, Thomas Powles, David W Markby, Jace Nielsen, Steven Lacy, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2018)

645 Background: C is approved for the treatment of advanced RCC after prior antiangiogenic therapy at 60 mg qd with dose reductions to 40 mg and 20 mg used to manage adverse events (AEs). In this study, ER analyses were used to evaluate the effect of C dose on progression-free survival (PFS) and safety endpoints at different apparent clearance (CL/F) values for pts in the phase 3 METEOR study (NCT01865747). Methods: Predicted steady-state C exposures were calculated for doses of 60, 40, and 20 mg in pts with CL/F values of 1.3, 2.23, and 3.3 L/hr; these values were based on population PK models and represent pts with low, average, and high CL/F, respectively. Time-to-event Cox proportional hazard ER models were used to characterize the relationship between predicted C exposure and the probability of PFS and 4 common C AEs: fatigue/asthenia (grade ≥3), palmar-plantar erythrodysesthesia (PPE; grade ≥1), diarrhea (grade ≥3), and hypertension (systolic BP &gt; 160 mmHg or diastolic BP &gt; 100 mmHg). Results: Among the 282 pts evaluated, predicted C CL/F values ranged from 0.51 to 7.24 L/hr. Predicted C exposure at the 60 mg dose ranged from 758 to 1923 ng/mL for representative pts with high and low CL/F (3.3 and 1.3 L/hr). A 60 mg dose for a high CL/F pt is predicted to yield C exposure similar to that of an average CL/F pt dosed at 40 mg (758 vs 748 ng/mL). At the 3 CL/F values evaluated, the hazard ratio (HR) for PFS modestly favored the 60 mg vs 40 mg dose, with the greatest impact on high CL/F pts (HR 1.13, 95% CI 1.10-1.16). 4 common C AEs are predicted to occur at lower rates at the 40 mg vs 60 mg dose; HRs ranged from 0.51-0.82 with the greatest effect in pts with low CL/F. Conclusions: Predicted C CL/F values and C exposures varied among pts with RCC in the METEOR study. ER models suggest that pts with high CL/F may have less favorable PFS outcomes at a starting dose of 40 mg vs the recommended 60 mg dose. Patients with low CL/F are predicted to have decreased rates of AEs at lower doses. Clinical trial information: NCT01865747. [Table: see text]
Comparing cabozantinib (C) treatment for a cohort of patients with metastatic clear cell (ccRCC) and variant histology renal cell carcinoma (vhRCC): A retrospective study.
Authors: Emily Lemke, Amishi Yogesh Shah, Pavlos Msaouel, Mehmet Asim Bilen, Eric Jonasch, Aradhana M. Venkatesan, Anuradha Chandramohan, Cihan Duran, Nizar M. Tannir, Matthew T. Campbell
Journal: Journal of Clinical Oncology (2018)

702 Background: Both the randomized METEOR and CABOSUN studies in ccRCC found substantial benefit for patients receiving (C). We have previously reported (C) to have significant activity in vhRCC. To date no comparative data exists in evaluating the utility of (C) in ccRCC and vhRCC. Methods: This is a retrospective study of patients with ccRCC and vhRCC who received (C) at a single center from 1/2014-9/2017. Data tabulated included baseline characteristics, toxicity, dose reductions, time on (C) and survival data. A blinded radiologist assessed the radiographic response using RECIST v1.1. Cox regression analysis of time to treatment failure (TTF) in ccRCC and vhRCC was performed, adjusting for age, gender, IMDC score, neutrophil to lymphocyte ratio (NLR), prior TKI treatment, and number of metastatic sites. Statistical analysis were performed using SPSS 23.0. Results:Time to treatment failure was significantly longer in vhRCC compared with ccRCC (16.1 vs 7.64 months, HR 0.42, 95%CI 0.22-0.79, p = 0.007). This difference persisted in the adjusted Cox regression model (HR 0.36, 95% CI 0.15-0.85, p = 0.02). Conclusions: In this retrospective comparative analysis of C treated vhRCC and ccRCC patients, C was found to have substantial activity in both cohorts of patients. The IMDC score was important to predict outcome. Both heavily pretreated patients with ccRCC and those with vhRCC appeared to have substantial benefit.[Table: see text]
Suicide: The Leading Cause of Violent Death
Authors: Bridget Kuehn
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
An Aid to Medical Interviews and Professional Development
Authors: Luka Vončina
Journal: BMJ (2005)

I would definitely recommend taking a look at this book. Most junior doctors in the United Kingdom will find it useful in their everyday practice and for their professional development. It's short (only 74 pages), packed with pertinent information, and written in a systematic, easy to read way.

Let's start at the end. The final chapter, which has valuable tips for job interviews, is definitely the highlight of the book. It gives advice …
IMPACT OF PREOPERATIVE ATRIAL FIBRILLATION IN PATIENTS WITH LEFT VENTRICULAR ASSIST DEVICE: A SYSTEMATIC REVIEW AND META-ANALYSIS
Authors: Pakpoom Tantrachoti, Saranapoom Klomjit, Wasawat Vutthikraivit, Pattara Rattanawong, Pavida Pachariyanon, Passisd Laoveeravat, Subhanudh Thavaraputta, Nandini Nair
Journal: Journal of the American College of Cardiology (2018)
SAFE OUTCOMES WITH NOVEL ORAL ANTICOAGULANTS IN OBESE PATIENTS UNDERGOING ELECTRICAL CARDIOVERSION FOR ATRIAL TACHYARRHYTHMIAS
Authors: Rachel Kaplan, Celso Diaz, Theresa Strzelczyk, Cindy You, Basil Saour, Michelle Fine, Amar Trivedi, Mark Shen, Prasongchai Sattayaprasert, Alexandru Chicos, Rishi Arora, Susan Kim, Albert Lin, Nishant Verma, Bradley Knight, Rod Passman
Journal: Journal of the American College of Cardiology (2018)
THE RELATIONSHIP BETWEEN TIMING OF PRASUGREL PRETREATMENT AND IN-STENT THROMBUS IMMEDIATELY AFTER PERCUTANEOUS CORONARY INTERVENTION FOR ACUTE CORONARY SYNDROME: AN OPTICAL COHERENCE TOMOGRAPHY STUDY
Authors: Yosuke Katayama, Takashi Kubo, Yasushi Ino, Yoshiki Matsuo, Hironori Kitabata, Akira Taruya, Kunihiro Shimamura, Yasutsugu Shiono, Atsushi Tanaka, Takeshi Hozumi, Takashi Akasaka
Journal: Journal of the American College of Cardiology (2018)
New centralised system for specialty training offers is to be introduced for 2013
Authors: Helen Jaques
Journal: BMJ (2012)

Junior doctors who apply for specialty training in the United Kingdom will from this year receive all their offers electronically through a new central system, the Department of Health has announced.

The UK Offers System for Medical Specialty Training will coordinate all round one and two offers for core and higher specialty training posts that start in 2013.

Previously, applicants to specialty training received offers individually from the royal colleges and deaneries that coordinated the applications. The respective royal colleges handled offers for medical …
TRPM2 Mediates Neutrophil Killing of Disseminated Tumor Cells
Authors: Maya Gershkovitz, Yaki Caspi, Tanya Fainsod-Levi, Ben Katz, Janna Michaeli, Saleh Khawaled, Shaya Lev, Lola Polyansky, Merav E. Shaul, Ronit V. Sionov, Leonor Cohen-Daniel, Rami I. Aqeilan, Yoav D. Shaul, Yasuo Mori, Rotem Karni, Zvi G. Fridlender, Alexander M. Binshtok, Zvi Granot
Journal: Cancer Research (2018)

Neutrophils play a critical role in cancer, with both protumor and antitumor neutrophil subpopulations reported. The antitumor neutrophil subpopulation has the capacity to kill tumor cells and limit metastatic spread, yet not all tumor cells are equally susceptible to neutrophil cytotoxicity. Because cells that evade neutrophils have greater chances of forming metastases, we explored the mechanism neutrophils use to kill tumor cells. Neutrophil cytotoxicity was previously shown to be mediated by secretion of H2O2 We report here that neutrophil cytotoxicity is Ca2+ dependent and is mediated by TRPM2, a ubiquitously expressed H2O2-dependent Ca2+ channel. Perturbing TRPM2 expression limited tumor cell proliferation, leading to attenuated tumor growth. Concomitantly, cells expressing reduced levels of TRPM2 were protected from neutrophil cytotoxicity and seeded more efficiently in the premetastatic lung.Significance: These findings identify the mechanism utilized by neutrophils to kill disseminated tumor cells and to limit metastatic spread. Cancer Res; 78(10); 2680-90. ©2018 AACR.
A 2-Step Cerebrospinal Algorithm for the Selection of Frontotemporal Lobar Degeneration Subtypes
Authors: Alberto Lleó, David J. Irwin, Ignacio Illán-Gala, Corey T. McMillan, David A. Wolk, Edward B. Lee, Vivianna M. Van Deerlin, Leslie M. Shaw, John Q. Trojanowski, Murray Grossman
Journal: JAMA Neurology (2018)

Cerebrospinal fluid (CSF) core Alzheimer disease (AD) biomarkers have shown an excellent capacity for the in vivo detection of AD. Previous studies have shown that CSF levels of phosphorylated tau (p-tau) also correlate with tau pathology in frontotemporal lobar degeneration (FTLD) after accounting for AD copathology.To develop an algorithm based on core AD CSF measures to exclude cases with AD pathology and then differentiate between FTLD-tau and FTLD transactive response DNA-binding protein of approximately 43kDa (FTLD-TDP).A case-control study at the University of Pennsylvania. Participants were selected from a database of 1796 patients included between 1992 and 2016 with different neurodegenerative diseases with available CSF. Three patient cohorts were included: a cohort of patients with sporadic, autopsy-confirmed FTLD and AD (n = 143); a cohort of patients with frontotemporal degeneration (FTD) with TDP-associated or tau-associated mutations (n = 60); and a living cohort of patients with syndromes highly predictive of FTLD (progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis; n = 62).Cerebrospinal fluid values of amyloid β1-42 (Aβ1-42), total tau (t-tau), and p-tau obtained using the INNO-BIA AlzBio3 (xMAP; Luminex) assay or INNOTEST enzyme-linked immunosorbent assay transformed using a previously validated algorithm. Sensitivities and specificities for differentiating AD from FTLD groups were calculated.This autopsy cohort included FTLD-tau (n = 27; mean [SD] age at onset, 60.8 [9.7] years), FTLD-TDP (n = 13; mean [SD] age at onset, 62.4 [8.5] years), AD (n = 89, mean [SD] age at onset, 66.5 [9.7] years); and mixed FTLD-AD (n = 14, mean [SD] age at onset, 70.6 [8.5] years).The p-tau/Aβ1-42 ratio showed an excellent diagnostic accuracy to exclude AD cases in the autopsy cohort with single neurodegenerative pathologies (area under the curve [AUC], 0.98; 95% CI, 0.96-1.00). Cerebrospinal fluid p-tau levels showed a good AUC (0.87; 95% CI, 0.73-1.00) for discriminating pure FTLD-TDP from pure FTLD-tau. The application of an algorithm using cutpoints of CSF p-tau to Aβ1-42 ratio and p-tau allowed a good discrimination of pure FTLD-TDP cases from the remaining FTLD-tau and mixed FTLD cases. The diagnostic value of this algorithm was confirmed in an independent cohort of living patients with progressive supranuclear palsy and FTD-amyotrophic lateral sclerosis (AUC, 0.9; 95% CI, 0.81-0.99). However, the algorithm was less useful in FTD cases carrying a pathogenic mutation (AUC, 0.58; 95% CI, 0.38-0.77) owing to elevated p-tau levels in TDP-associated mutation carriers.Alzheimer disease CSF core biomarkers can be used with high specificity for the in vivo identification of patients with pure FTLD-TDP and FTLD-tau when accounting for comorbid AD and genetic status.
Your Own Pharmacy: The Guide for GPs
Authors: Robin Fox
Journal: BMJ (2005)

OK, so not one for the coffee table, but there is an opportunity here. If you do own your own pharmacy then do not read this book. If, however, like most of us you don't, read on.

The main thrust is about the new opportunity of owning a pharmacy within your existing or new premises. This opportunity is open to both nondispensing and dispensing practices. Essentially, in order to open …
SURGICAL MANAGEMENT OF NONOBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY: CLINICAL OUTCOME OF MYECTOMY IN 94 PATIENTS WITH APICAL HCM
Authors: Anita Nguyen, Hartzell Schaff, Rick A. Nishimura, Jeffrey Geske, Joseph Dearani, Steve Ommen
Journal: Journal of the American College of Cardiology (2018)
Early versus delayed initiation of salvage androgen deprivation therapy and the risk of prostate cancer-specific mortality.
Authors: Brandon Arvin Virgil Mahal, Ming-Hui Chen, Andrew A. Renshaw, Philip W. Kantoff, Anthony Victor D'Amico
Journal: Journal of Clinical Oncology (2018)

189 Background: We sought to ascertain whether there is an association between prostate cancer (PC)-specific mortality (PCSM) and salvage androgen deprivation therapy (ADT) timing amongst men with short versus long prostate-specific antigen doubling times (PSA-DT)s. Methods: The study cohort was selected from 206 men with localized unfavorable-risk PC who were randomized to radiation therapy (RT) or RT plus 6 months of ADT between 1995 and 2001. Fifty-four men who received salvage ADT for PSA failure after a median follow up of 18.72 years following randomization defined the study cohort. Fine-Gray competing risks regression analyzed whether the timing of salvage ADT was associated with an increased risk of PCSM after adjusting for age, comorbidity, known PC prognostic factors, and previously identified interactions. Results: After a median follow-up of 5.68 years (IQR 3.05 - 9.56) following salvage ADT 49 of the 54 men (91%) died, 27 from PC (54% of deaths). Increasing PSA-DT as a continuous covariate was associated with a decreasing risk of PCSM (adjusted hazard ratio [AHR] 0.33, 95% CI 0.13, 0.82; P=0.02). Amongst men with a long PSA-DT (≥6 months), initiating salvage ADT later (PSA&gt;12ng/mL, upper quartile) versus earlier was associated with an increased risk of PCSM (AHR 8.84, 95% CI 1.99-39.27; P=0.004); whereas for men with a short (&lt;6 months) PSA-DT (AHR 1.16, 95% CI 0.38-3.54; P=0.79) this was not true. Conclusions: Early initiation of salvage ADT for post-RT PSA recurrence in men with a PSA-DT of 6 months or more may reduce the risk of PCSM, arguing against the unproven assumption that patients with a short PSA-DT are those most likely to benefit from early initiation of salvage ADT. Clinical trial information: NCT00116220.
Impact of sexual orientation on contemporary rates of prostate cancer screening.
Authors: Daniel Pucheril, Matthew D. Ingham, Dimitar V. Zlatev, Sebastian Berg, Matthew Mossanen, Steven Lee Chang, Adam S. Kibel, Quoc-Dien Trinh
Journal: Journal of Clinical Oncology (2018)

122 Background: Despite increasing societal acceptance of non-heterosexual persons, sexual minorities continue to face discrimination. The effect of non-heterosexual orientation on adoption of cancer preventive services, particularly prostate cancer screening (PSAS), is not clearly known. We hypothesize that male sexual minorities are less likely to receive PSAS compared to heterosexual (HTS) males. Methods: The 2014-16 Behavioral Risk Factor Surveillance System was queried for males 40-69, without a history of prostate cancer, and having answered all sexual orientation (SO) questions. PSAS occurred if a respondent had a PSA test within the last two years for reasons other than “a prostate problem” or “for prostate cancer”. Descriptive statistics were generated for demographic covariates stratified by year and SO [HTS, homosexual (HMS), bisexual (BIS), transgender (TGR), other, and refused]. The Chi-Square test was used to compare the distribution of covariate proportions amongst SO categories within each year. Multivariable regression was used to determine the independent effect of SO and other covariates on receipt of PSAS in this cohort. Results: A weighted 49.2 million individuals (n = 86,893) met inclusion criteria. In 2014 and 2016, 94% and 93% of the cohort identified as HTS. In both years, a higher proportion of HMS (2014: 40.5%, 2016: 47.4) and BIS (2014: 30.3%, 2016: 31.0%) respondents were college graduates compared to HTS males (2014: 28.8%, 2016: 28.9%). In 2014, rates of PSAS were higher amongst HMS (34.9%), BIS (37.1%) and TGR (37.5%) individuals compared to HTS individuals (34.5%). In 2016, rates of PSAS were clinically similar among HTS (30.4%), HMS (30.2%), BIS (30.1%), and TGR (27.8%) individuals. In the multivariable analysis, increasing age (65-69 OR 8.93, 95%CI 7.80-10.22) and education level (College Graduate OR 2.21, 95%CI 1.93-2.54) along with insurance coverage (OR 2.15, 95%CI 1.85-2.51) and a personal physician (OR 2.88, 95%CI 2.59-3.20) were associated with higher odds of PSAS. Aside from HMS orientation (OR 1.30, 95%CI 1.04-1.62), SO was not an independent predictor of PSAS. Conclusions: Based on this nationally representative sample, disparities in regards to PSAS are not apparent for non-HTS males.
P013 Porphyromonas gingivalis infection linked to ra onset and ANTI TNF alpha treatment non-response
Authors: M Jenning, B Marklein, Y Ytterberg, A Catarina, D Schaardenburg, G Bürmester, K Skriner
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Introduction</h3> Differences in enzymatic activity and pathogenic impact of <i>Porphyromonas gingivalis</i> (<i>P.g.</i>) peptidylarginine deiminase (PPAD) for development of RA have been published, confounded by different PPAD variations and methods used. <h3>Objectives</h3> Enzymatic active PPAD isolated from an RA patient (RA-PPAD) was first time linked to citrullination of RA autoantigens, diagnosis, therapy response and RA-onset. <h3>Methods</h3> Recombinant RA-PPAD cloned, verified by DNA sequencing and expressed in <i>Escherichia coli and purified.</i> RA-PPAD and its enzymatic activity was analysed using 2D-Elektrophoresis, mass spectrometry (MS), immunoblot and ELISA. <h3>Results</h3> RA-PPAD autocitrullinates amino acid position 63 (aa<sub>63</sub>) and exhibits so far two new amino acid mutations aa<sub>73</sub> F to L and aa<sub>447</sub> E to V. Anti-citrullinated RA-PPAD antibodies were detected in 38% (n=36) of patients with RA, but were absent in Systemic lupus erythematosus (n=30), Osteoarthritis (n=36) and control sera (n=23). Twenty percent of RA patients (n=30) showed an increase in antibody-titre against citrullinated RA-PPAD after RA onset. High antibody titre against the cit-PPAD-peptide of 15aa (CPP) derived from the autocitrullination site (R<sub>63</sub>) correlates with TNFα-inhibitor (TBA) non-response (n=61). Anti-CPP levels correlate with DAS28,rheumatoid factor, α-CCP 2 levels and increase with age. RA-PPAD is able to citrullinate internal arginines in fibrinogen, vimentin, hnRNP-A2/B1 and histone H1. This internal citrullination-sites are recognised by RA sera and able to bind HLA401. <h3>Conclusions</h3> Failure of <i>P.g.</i> clearance in RA patients may lead to excessive exposure of citrullinated self-antigens and bacterial antigens inducing immune-mimicry. <i>P.g.</i> infection can be linked to RA and its correlation to TBA non-response leads to the suggestion to clear <i>P.g</i> infection before α-TNF treatment. <h3>Disclosure of interest</h3> None declared
Abstract 20473: Impact of p53 activation on Lesional Macrophage Proliferation And Atherosclerosis In Mice
Authors: Volkan I Sayin
Journal: Circulation (2016)

Rationale:  Cell proliferation and cell cycle control mechanisms are believed to play central roles in the pathogenesis of atherosclerosis. The transcription factor Zinc fingerprotein 148 (Zfp148) was recently shown to maintain cell proliferation under oxidative conditions by suppressing p53, a checkpoint protein that arrests proliferation inresponse to various stressors. It is established that inactivation of p53 accelerates atherosclerosis, but whether increased p53 activation confers protection against thedisease remains to be determined.   Objective:  We aimed to test the hypothesis that Zfp148 deficiency reduces atherosclerosis by unleashing p53 activity.   Methods and Results:  Mice harbouring a gene-trap mutation in the Zfp148 locus (Zfp148gt/+) were bred onto the Apoe-/- genetic background and fed a high-fat or chowdiet. Loss of one copy of Zfp148 markedly reduced atherosclerosis without affecting lipid metabolism. Bone marrow transplantation experiments revealed that the effectorcell is of hematopoietic origin. We next investigated whether p53 is part of the underlying mechanism. Peritoneal macrophages from Zfp148gt/+Apoe-/- mice showedincreased levels of phosphorylated p53 compared to controls, and atherosclerotic lesions from Zfp148gt/+Apoe-/- mice contained fewer proliferating cells and moreapoptotic cells. Zfp148gt/+Apoe-/- mice were further crossed with p53-null mice (Trp53-/-). There was no difference in atherosclerosis between Zfp148gt/+Apoe-/- mice andcontrols on a Trp53+/- genetic background.   Conclusions:  Zfp148 deficiency increases p53 activity and protects against atherosclerosis without affecting lipid metabolism. The protective effect is entirely dependent onp53 and suggests that drugs that increase p53 activity may be useful in the treatment of atherosclerosis.